How big data M&A performed in the pharmaceutical industry in Q2 2023

In value terms, big data-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume decreased by 57% in Q2 2023 versus the previous quarter.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Bank of America; Barclays; Canaccord Genuity Group with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were CMS Legal Services EEIG; Gibson, Dunn & Crutcher; Hogan Lovells International with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s Big Data in Pharmaceuticals – Thematic Research, buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.

How the Denver Bulldogs emerged as Aussie rules football powerhouse, community beacon over last 25 years – The Cannabist

Around midnight in the parking lot of a Denver bar a quarter century ago, the Colorado version of a classic Australian sport was born. Paul

October 5, 2024

Women with HIV experience accelerated DNA aging, study shows

Women with HIV experience accelerated DNA aging, a phenomenon that can lead to poor physical function, according to a study led by Stephanie Shiau, an

February 15, 2024

Generative AI-focused biotech startup Evozyne raises $81m – Pharmaceutical Technology

Generative AI is being touted as a transformer of the drug discovery process, with benefits including reducing the time to market for new drugs, lowering

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.